FB-TW

Showing posts with label Pubmed. Show all posts
Showing posts with label Pubmed. Show all posts

Tuesday, February 18, 2014

Effect of wheat on irritable bowel syndrome- FreeTheAnimal

Looks Like Dr. William Davis Was Right in Wheat Belly

February 18th, 2014     

Well what do you know?

I've been following Dr. Davis for a long time and have really applauded a lot of the work he was doing over the years getting really good results for people, primarily by getting them off wheat and getting their vitamin D levels up. The results often showed up in significant reductions in heart scan calcification scores. Davis in a cardiologist. Since I was pretty hardcore Paleo at the time, it made a lot of sense, but I attributed that success mostly to the removal of grains period.

Then comes his book—Wheat Belly: Lose the Wheat, Lose the Weight, and Find Your Path Back To Health

========================================================
The above is a quote from here.


Below is a copy of the abstract from  a double-blinded randomised dietary intervention trial. The original can be found here.
=====================================================================

Effect of Triticum turgidum subsp. turanicum wheat on irritable bowel syndrome: a double-blinded randomised dietary intervention trial.

Abstract

The aim of the present study was to examine the effect of a replacement diet with organic, semi-whole-grain products derived from Triticum turgidum subsp. turanicum (ancient) wheat on irritable bowel syndrome (IBS) symptoms and inflammatory/biochemical parameters. A double-blinded randomised cross-over trial was performed using twenty participants (thirteen females and seven males, aged 18-59 years) classified as having moderate IBS. Participants received products (bread, pasta, biscuits and crackers) made either from ancient or modern wheat for 6 weeks in a random order. Symptoms due to IBS were evaluated using two questionnaires, which were compiled both at baseline and on a weekly basis during the intervention period. Blood analyses were carried out at the beginning and end of each respective intervention period. During the intervention period with ancient wheat products, patients experienced a significant decrease in the severity of IBS symptoms, such as abdominal pain (P< 0·0001), bloating (P= 0·004), satisfaction with stool consistency (P< 0·001) and tiredness (P< 0·0001). No significant difference was observed after the intervention period with modern wheat products. Similarly, patients reported significant amelioration in the severity of gastrointestinal symptoms only after the ancient wheat intervention period, as measured by the intensity of pain (P= 0·001), the frequency of pain (P< 0·0001), bloating (P< 0·0001), abdominal distension (P< 0·001) and the quality of life (P< 0·0001). Interestingly, the inflammatory profile showed a significant reduction in the circulating levels of pro-inflammatory cytokines, including IL-6, IL-17, interferon-γ, monocyte chemotactic protein-1 and vascular endothelial growth factor after the intervention period with ancient wheat products, but not after the control period. In conclusion, significant improvements in both IBS symptoms and the inflammatory profile were reported after the ingestion of ancient wheat products.
PMID: 24521561 [PubMed - as supplied by publisher]
===================================================================
Read the complete articles here and here.

Saturday, February 8, 2014

Statins, neuromuscular degenerative disease and an ALS-like syndrome

Statins, neuromuscular degenerative disease and an amyotrophic lateral sclerosis-like syndrome: an analysis of individual case safety reports from vigibase.

Abstract

BACKGROUND:

The WHO Foundation Collaborating Centre for International Drug Monitoring (Uppsala Monitoring Centre [UMC]) has received many individual case safety reports (ICSRs) associating HMG-CoA reductase inhibitor drug (statin) use with the occurrence of muscle damage, including rhabdomyolysis, and also peripheral neuropathy. A new signal has now appeared of disproportionally high reporting of upper motor neurone lesions.

AIM AND SCOPE:

The aim of this paper is to present the upper motor neurone lesion cases, with other evidence, as a signal of a relationship between statins and an amyotrophic lateral sclerosis (ALS)-like syndrome. The paper also presents some arguments for considering that a spectrum of severe neuromuscular damage may be associated with statin use, albeit rarely. The paper does not do more than raise the signal for further work and analysis of what must be regarded as a potentially very serious and perhaps avoidable or reversible adverse reaction, though it also suggests action to be taken if an ALS-like syndrome should occur in a patient using statins.

METHODS:

The 43 reports accounting for the disproportional reports in Vigibase (the database of the WHO Programme for International Drug Monitoring) are summarised and analysed for the diagnosis of an ALS-like syndrome. The issues of data quality and potential reporting bias are considered.

RESULTS:

'Upper motor neurone lesion' is a rare adverse event reported in relationship to drugs in Vigibase (a database containing nearly 4 million ICSRs). Of the total of 172 ICSRs on this reported term, 43 were related to statins, of which 40 were considered further: all but one case was reported as ALS. In 34/40 reports a statin was the sole reported suspected drug. The diagnostic criteria were variable, and seven of the statin cases also had features of peripheral neuropathy. Of a total of 5534 ICSRs of peripheral neuropathy related to any drug in Vigibase, 547 were on statins. The disproportional reporting of statins and upper motor neurone lesion persisted after age stratification, and such disproportionality was not seen for statins and Parkinson's disease, Alzheimer's disease, extrapyramidal disorders, or multiple sclerosis-like syndromes.

DISCUSSION:

Because the cases were sometimes atypical we propose the use of the term 'ALS-like syndrome' and speculate whether this is part of a spectrum of rare neuromuscular damage. The diagnosis of ALS is often problematic, and the insidiousness and chronicity of the disease make causality with a drug difficult to assess. The disproportionally high reporting makes this an important signal nevertheless, since ALS is serious clinically and statins are so widely used. Wide use of the statins also makes a chance finding more probable, but is unlikely to cause disproportional reporting when there are no obvious biases identified.

CONCLUSION:

We emphasise the rarity of this possible association, and also the need for further study to establish whether a causal relationship exists. We do advocate that trial discontinuation of a statin should be considered in patients with serious neuromuscular disease such as the ALS-like syndrome, given the poor prognosis and a possibility that progression of the disease may be halted or even reversed.
====================================================================
Read the complete article here.

Thursday, January 9, 2014

Dietary Iron Intake & Body Iron Stores Are Associated with Coronary Heart Disease


Dietary Iron Intake and Body Iron Stores Are Associated with Risk of Coronary Heart Disease

Abstract

The link between iron intake as well as body iron stores and coronary heart disease (CHD) has been contentiously debated, and the epidemiologic evidence is inconsistent. We aimed to quantitatively summarize the literature on the association between dietary iron intake/body iron stores and CHD risk by conducting a meta-analysis of prospective cohort studies. PubMed was used to find studies published through June 2013 in peer-reviewed journals. Embase or a hand search of relevant articles was used to obtain additional articles. The pooled RRs of CHD incidence and mortality with 95% CIs were calculated by using either a random-effects or fixed-effects model, as appropriate. Twenty-one eligible studies (32 cohorts) including 292,454 participants with an average of 10.2 y of follow-up were included. Heme iron was found to be positively associated with CHD incidence (RR: 1.57; 95% CI: 1.28, 1.94), whereas total iron was inversely associated (RR: 0.85; 95% CI: 0.73, 0.999). Neither heme-iron nor total iron intakes were significantly associated with CHD mortality. Both transferrin saturation and serum iron were inversely related to CHD incidence [RR (95% CI): 0.76 (0.66, 0.88) and 0.68 (0.56, 0.82), respectively], but only transferrin saturation was inversely associated with CHD mortality (RR: 0.85; 95% CI: 0.73, 0.99). In conclusion, total iron intake and serum iron concentrations were inversely associated with CHD incidence, but heme iron intake was positively related to CHD incidence. Elevated serum transferrin saturation concentration was inversely associated with both CHD incidence and mortality. Future research is needed to establish the causal relation and to elucidate potential mechanisms.
==================================================================
Read the complete article here.

My 'take away' points from this abstract:
1. The link between iron intake as well as body iron stores and coronary heart disease (CHD) has been contentiously debated.
2. the epidemiologic evidence is inconsistent
3. Heme iron was found to be positively associated with CHD incidence
4. total iron was inversely associated with CHD incidence
5. Neither heme-iron nor total iron intakes were significantly associated with CHD mortality
6. Both transferrin saturation and serum iron were inversely related to CHD incidence
7. heme iron intake was positively related to CHD incidence and mortality.
8. Elevated serum transferrin saturation concentration was inversely associated with both CHD incidence and mortality

Monday, April 1, 2013

Highly Effective, But Often Overlooked - Niacin

The Safest Cholesterol Treatment

The safest, most effective, and cheapest treatment for high cholesterol is a vitamin that costs 7 cents per pill, according to a new report from Orthomolecular Medicine News Service (OMNS), a nonprofit research group in Wichita, Kansas.

Vitamin B3—also called niacin or nicotinic acid—has been safely used for 60 years to control cholesterol, with some 42,000 scientific papers in PubMed describing its benefits and effects.

“Unlike statin drugs, which mainly reduce LDL cholesterol, niacin is a very safe, effective treatment for all lipid issues, improving levels of both good and bad cholesterol and triglycerides, ” says Bradley Bale, MD, medical director of the Heart Health Program for Grace Clinic in Lubbock, Texas.
One landmark study published in Journal of the American College of Cardiology found that at therapeutic doses, niacin boosted HDL by up to 35 percent and cut triglycerides by as much as 50 percent.

Most remarkably, when the researchers tracked the 8,431 participants—all of whom had suffered heart attacks prior to enrolling in the study—for 15 years, those on niacin had a 26 percent lower risk for both heart attacks and strokes, even after treatment was discontinued, compared to those taking a placebo.

Highly Effective, But Often Overlooked

Despite some 42,000 scientific papers in PubMed describing niacin’s effectiveness and medical uses, it’s remained the ugly duckling of heart medicines, for a variety of reasons.

“The simple answer is to follow the money,” contends OMNS. “Cholesterol-controlling drugs [such as statins] are cash cows for the trillion-dollar-per-year pharmaceutical industry,” while there’s no marketing push to persuade medical providers to recommend a cheap, OTC remedy like niacin.

In his practice, Dr. Bale typically recommends niacin for the following patients, if medically appropriate:
  • People with high cholesterol who can’t tolerate statin drugs. About 20 percent of statin users quit taking their medication due to side effects.
  • Patients with complex lipid issues, such as low levels of heart-protective HDL (good) cholesterol and high triglycerides (a type of blood fat).
  • People with inherited cholesterol disorders, such as elevated levels of lipoprotein (a), a type of cholesterol that triples heart attack risk and does not respond to statins. Taking niacin can reduce lipoprotein (a) levels by up to 40 percent, according to the European Atherosclerosis Society.
  • Patients whose cholesterol problems aren’t responding to statins. Several studies show that statins plus niacin is more effective than statins alone.

Side Effects of Niacin

In doses typically used to control cholesterol the vitamin can have an annoying side effect known as “the niacin flush,” a temporary and sometimes itchy or tingling redness of the skin that lasts about 30 to 60 minutes.

“Doctors know that if they advise niacin, they get calls from patients complaining about flushing, particularly at first,” says Dr. Bale. “However, this problem is harmless and can often be avoided by starting with a low dose that’s gradually increased.”Patients who experience flushing initially will typically find that the problem disappears or greatly diminishes over time.

While “non-flush” and extended-release forms of niacin are available, they appear to be less effective or may even have dangerous side effects, Dr. Bale adds. “There are two pathways through which the body can metabolize niacin, and the one that doesn’t cause flushing is more likely to harm the liver.”
Dr. Bale advises avoiding non-flush or extended-release formulations. In addition, niacin should only be used under the supervision of a healthcare provider, after a full discussion of the potential risks and benefits.

Like statins, niacin can cause muscle problems in some patients. It can also spark flare-ups in people with gout, and may contribute to GI bleeding in patients with ulcers, cautions Dr. Bale. “Any cholesterol treatment can cause side effects, but compared to statins, niacin is relatively safe.”


A Controversial Niacin Study

In March, results of a highly publicized study of Tredaptive, an experimental drug containing extended-release niacin plus an anti-flushing drug called laropiprant, were interpreted by the media as showing that niacin may have dangerous side effects.

In the study, 25,673 patients who were already being treated with statins were randomly divided into 2 groups. One group took a statin drug plus Tredaptive and the other group received the same dose of statin along with a placebo.

Patients taking Treadaptive had higher rates of bleeding (2.5 percent vs. 1.9 percent) and infections (8 percent vs. 6.6 percent), as well as higher rates of new onset diabetes (9.1 percent vs. 7.3 percent). Nor did the patients on the experimental drug have lower rates of heart attack or stroke.

The study was halted prematurely, after four years, due to these problems and the maker of the experimental drug, Merck, announced that it wouldn’t be seeking FDA approval.

While media reports blamed these problems on niacin, Dr. Bale and other experts point out these adverse effects haven’t been seen in numerous previous studies of the vitamin on its own, so the anti-flushing drug is the likely culprit.

“Niacin is being thrown under the bus when it’s an inexpensive, effective treatment that’s been used very safely for decades,” says Dr. Bale. “What this study is telling us is that this particular no-flush drug doesn’t work and can have significant side effects.”
==================================================================
Read the complete article here

Sunday, March 10, 2013

Genetic determinants of statin intolerance - PubMed


Genetic determinants of statin intolerance.

2007 Mar 21;6:7.

Source

Schulich School of Medicine and Dentistry, University of Western Ontario and Vascular Biology Research Group, Robarts Research Institute, London, Ontario, Canada. jisun.oh@utoronto.ca

Abstract

BACKGROUND:

Statin-related skeletal muscle disorders range from benign myalgias--such as non-specific muscle aches or joint pains without elevated serum creatinine kinase (CK) concentration--to true myositis with >10-fold elevation of serum CK, to rhabdomyolysis and myoglobinuria. The genetic basis of statin-related muscle disorders is largely unknown. Because mutations in the COQ2 gene are associated with severe inherited myopathy, we hypothesized that common, mild genetic variation in COQ2 would be associated with inter-individual variation in statin intolerance. We studied 133 subjects who developed myopathy on statin monotherapy and 158 matched controls who tolerated statins without incident or complaint.

RESULTS:

COQ2 genotypes, based on two single nucleotide polymorphisms (SNP1 and SNP2) and a 2-SNP haplotype, all showed significant associations with statin intolerance. Specifically, the odds ratios (with 95% confidence intervals) for increased risk of statin intolerance among homozygotes for the rare alleles were 2.42 (0.99 to 5.89), 2.33 (1.13 to 4.81) and 2.58 (1.26 to 5.28) for SNP1 and SNP2 genotypes, and the 2-SNP haplotype, respectively.

CONCLUSION:

These preliminary pharmacogenetic results, if confirmed, are consistent with the idea that statin intolerance which is manifested primarily through muscle symptoms is associated with genomic variation in COQ2 and thus perhaps with the CoQ10 pathway.
PMID: 17376224 [PubMed - indexed for MEDLINE]
PMCID: PMC1832194
==============================================================
Read the full article here.

Friday, September 28, 2012

Statin use is associated with an increased prevalence and extent of coronary plaques possessing calcium


Statins use and coronary artery plaque composition: Results from the International Multicenter CONFIRM Registry.

Source

Cedars-Sinai Heart Institute and Department of Imaging, Cedars-Sinai Medical Center, Los Angeles, CA, USA. Electronic address: Ryo.Nakazato@cshs.org.

Abstract

OBJECTIVE:

The effect of statins on coronary artery plaque features beyond stenosis severity is not known. Coronary CT angiography (CCTA) is a novel non-invasive method that permits direct visualization of coronary atherosclerotic features, including plaque composition. We evaluated the association of statin use to coronary plaque composition type in patients without known coronary artery disease (CAD) undergoing CCTA.

METHODS:

From consecutive individuals, we identified 6673 individuals (2413 on statin therapy and 4260 not on statin therapy) with no known CAD and available statin use status. We studied the relationship between statin use and the presence and extent of specific plaque composition types, which was graded as non-calcified (NCP), mixed (MP), or calcified (CP) plaque.

RESULTS:

The mean age was 59 ± 11 (55% male). Compared to the individuals not taking statins, those taking statins had higher prevalence of risk factors and obstructive CAD. In multivariable analyses, statin use was associated with increased the presence of MP [odds ratio (OR) 1.46, 95% confidence interval (CI) 1.27-1.68), p < 0.001] and CP (OR 1.54, 95% CI 1.36-1.74, p < 0.001), but not NCP (OR 1.11, 95% CI 0.96-1.29, p = 0.1). Further, in multivariable analyses, statin use was associated with increasing numbers of coronary segments possessing MP (OR 1.52, 95% CI 1.34-1.73, p < 0.001) and CP (OR 1.52, 95% CI 1.36-1.70, p < 0.001), but not coronary segments with NCP (OR 1.09, 95% CI 0.94-1.25, p = 0.2).

CONCLUSION:

Statin use is associated with an increased prevalence and extent of coronary plaques possessing calcium. The longitudinal effect of statins on coronary plaque composition warrants further investigation.

Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.
PMID: 22981406 [PubMed - as supplied by publisher]
====================================================================
Read the complete article here.

Wednesday, August 22, 2012

Effects of low carbohydrate diets on cardiovascular risk factors.

Systematic review and meta-analysis of clinical trials of the effects of low carbohydrate diets on cardiovascular risk factors.

Source

Centro Hospitalar Vila Nova Gaia/Espinho, Gaia, Portugal Centro Hospitalar do Porto, Porto, Portugal Faculdade de Medicina da Universidade do Porto, Porto, Portugal Veteran Affairs Medical Center, Durham, NC, USA Duke University Medical Center, Durham, NC, USA.

Abstract

A systematic review and meta-analysis were carried out to study the effects of low-carbohydrate diet (LCD) on weight loss and cardiovascular risk factors (search performed on PubMed, Cochrane Central Register of Controlled Trials and Scopus databases). A total of 23 reports, corresponding to 17 clinical investigations, were identified as meeting the pre-specified criteria. Meta-analysis carried out on data obtained in 1,141 obese patients, showed the LCD to be associated with significant decreases in body weight (-7.04 kg [95% CI -7.20/-6.88]), body mass index (-2.09 kg m(-2) [95% CI -2.15/-2.04]), abdominal circumference (-5.74 cm [95% CI -6.07/-5.41]), systolic blood pressure (-4.81 mm Hg [95% CI -5.33/-4.29]), diastolic blood pressure (-3.10 mm Hg [95% CI -3.45/-2.74]), plasma triglycerides (-29.71 mg dL(-1) [95% CI -31.99/-27.44]), fasting plasma glucose (-1.05 mg dL(-1) [95% CI -1.67/-0.44]), glycated haemoglobin (-0.21% [95% CI -0.24/-0.18]), plasma insulin (-2.24 micro IU mL(-1) [95% CI -2.65/-1.82]) and plasma C-reactive protein, as well as an increase in high-density lipoprotein cholesterol (1.73 mg dL(-1) [95%CI 1.44/2.01]). Low-density lipoprotein cholesterol and creatinine did not change significantly, whereas limited data exist concerning plasma uric acid. LCD was shown to have favourable effects on body weight and major cardiovascular risk factors; however the effects on long-term health are unknown.
======================================================================
Emphasis added by bd.
Read the full article here.

 

Tuesday, June 19, 2012

Alzheimer's: statin cure claims unfounded


Alzheimer's: statin cure claims unfounded

Wed, 04 Apr 2012 15:33:00 EST

Cholesterol-lowering statin drugs “could stave off the symptoms of Alzheimer’s”, according to The Daily Telegraph. The front page of the Daily Express even boldly reported: “Statins halt Alzheimer’s.”

These attention-grabbing claims could easily lead readers to assume there has been a major breakthrough in the fight to cure Alzheimer’s disease. However, they are based on a small laboratory study which used mice that were bred to display signs of Alzheimer’s.

The early-stage research showed that the cholesterol-lowering drug simvastatin could improve learning and memory in mice genetically engineered to produce excess levels of amyloid protein in the brain, a characteristic feature of Alzheimer’s disease in humans. However, these improvements were only seen in younger mice, not older ones. The researchers took this to mean that statins would only be effective for blocking early-stage disease. The research also demonstrated that simvastatin caused some improvement in blood vessel function, which some researchers believe to be involved in developing the condition.

Even though these seem like positive results in mice, research has already looked directly at whether statins can stop Alzheimer’s and other forms of dementia in humans. For example, two recent high-quality reviews of research into statins and dementia suggest that there is no evidence that statins provide any specific benefit to humans with Alzheimer’s. While the new research suggests that the timing of statin use may allow it to have an effect, the evidence is far from conclusive and this would need to be explored further in a laboratory. Given the limitations of this research and the uncertainty over its results, the headline “Statins halt Alzheimer’s” is wildly misleading.

Dr Simon Ridley, head of research at Alzheimer’s Research UK, has put the study into context in a statement for Behind the Headlines. He said: “People should view the results with caution until further research has teased out how simvastatin might be working in these mice, and more importantly, until there is any significant new clinical trial data in humans.”

Where did the story come from?


The study was carried out by researchers from McGill University, Canada, and was funded by the Canadian Institutes of Health Research and the Heart and Stroke Foundation of Canada. The study was published in the peer-reviewed Journal of Neuroscience.

Newspaper headlines about this research were generally misleading and suggested that it directly applies to humans. Most media reports took a few paragraphs, and in some cases half the article, to inform readers of the key fact that this research was carried out in mice and not humans. While the Daily Express’ headline suggests that statins have been proven to “halt Alzheimer’s”, this is not justified by the newly published research. In fact, the current body of high-quality research on this topic suggests the opposite is true.


What kind of research was this?


This laboratory study assessed the effect of simvastatin on different signs and symptoms of a mouse model of Alzheimer’s disease. Simvastatin is a widely used statin drug, which can control levels of cholesterol in the body. Around the world, many millions of middle-aged and elderly people take statins. To date, analysis of these populations has not detected any protective effect of the drug against dementia, including Alzheimer’s.

Laboratory studies in mice represent the early stages of medical research. During these mice-based studies, researchers are able to manipulate mice into displaying key characteristics of human disease, which they can then study in detail to better understand the condition in humans. For example, mice may be genetically modify to have biological characteristics similar to a human disease. However, there are key differences between mice and men, and early, experimental results from studies in mice may not always translate into similar findings in humans.

Alzheimer’s disease is characterised by the presence of deposits of the protein beta-amyloid in brain cells. These deposits are also known as amyloid plaques. These can interfere with the normal functioning of brain cells, causing the symptoms of memory loss and other deterioration in cognitive function commonly associated with Alzheimer’s disease. The authors of this study also said that Alzheimer’s is associated with problems in the blood vessels and blood circulation in the brain, and that previous research suggests this compromised blood flow could be related to the progression of Alzheimer’s.

Because statins can help keep blood vessels free of fatty build-up, some people have speculated that they could have a role in preventing Alzheimer’s disease. Previous reviews have not found an apparent link between statins and Alzheimer’s. However, the authors of this new research say recent evidence suggests that the cholesterol-lowering drugs may have beneficial effects on the development and progression of Alzheimer’s disease.

What did the research involve?


This study involved mice that were bred to produce excessive amounts of beta-amyloid protein in their brains, thereby mimicking the key biological characteristic of Alzheimer’s in humans. The research looked at the effect of the statin drug simvastatin on the levels of amyloid in the brain, as well as its effects on blood flow and blood vessel function in the brain.

The study used three main types of mice:

  • mice bred to have Alzheimer’s-like disease who received simvastatin (treatment group)
  • mice bred to have Alzheimer’s-like disease who didn’t receive simvastatin (control group)
  • mice that were not bred to have Alzheimer’s-like disease or receive simvastatin (natural group)

Simvastatin was given to the treatment group mice in their drinking water, while controls were given the same amount of water without the statin. Simvastatin was administered at 20mg per kilo of body weight per day for 3 days. This was increased to 30mg/kg/day for 4 days, and then to 40mg/kg/day for the rest of the treatment.

The treatment group was further divided into two age groups: adult and aged. Adult mice were six months old and had been treated with statins from three months of age for a period of three months. Aged mice were twelve months old and had been treated from six months of age for six months. Total cholesterol levels were measured to assess the effect of the statin.

Spatial memory and learning were assessed with a commonly used water maze test. This involves placing a mouse into a small pool of water containing an escape platform hidden beneath the water’s surface. Visual cues indicate its location, and researchers record how quickly the mouse learns the location of the platform on repeated attempts. The visual cues and platform location can be changed to further assess learning and memory.

Three days after they had completed the maze task, mice were anaesthetised and the blood flow in their brains was measured using a standard technique. This involved using lasers to gauge the amount of fluid moving through their blood vessels. In a subset of mice, a small sample of artery blood vessel tissue was taken from their brain and subjected to laboratory experiments. These were designed to assess its ability to contract and relax as a normal functioning blood vessel should.

The researchers then used appropriate statistical analysis techniques to examine their results.

What were the basic results?


The key finding of this study was that simvastatin fully restored short- and long-term memory in adult mice, but not in aged mice. The researchers found that these beneficial effects occurred without a decrease in the amount of amyloid plaque found in the brains of the mice.

In addition, simvastatin restored key aspects of the functionality of the arteries in the brains of mice with Alzheimer’s disease. This functionality was impaired in mice that did not receive the statin.

How did the researchers interpret the results?


The researchers concluded that simvastatin, and possibly other brain-penetrating statins, show “high therapeutic promise” in early Alzheimer’s disease and in patients with vascular disease who are at risk of developing Alzheimer’s disease.

Conclusion


News reports of this research have ranged from optimistic to misleading. The study’s early mouse-based results need to be viewed in context, particularly as no benefit of statin use on Alzheimer’s has been found when directly examined in humans.

This study shows that the cholesterol-lowering drug simvastatin could improve blood vessel function and learning and memory in mice with features of Alzheimer’s-like disease, but only when given “early in the disease process” (when the mice were at a younger age). However, improved performance in a water maze may not necessarily demonstrate reversal of Alzheimer’s, particularly as the researchers found no decrease in the amount of amyloid plaque found in the brains of the mice. This means that even in mice, the statin had no effect on amyloid, a key characteristic in the human form of the disease.

Furthermore, a recent systematic review of the literature on statins and dementia (including Alzheimer’s disease, which is one type of dementia with strict diagnostic criteria) concluded that the use of statins to prevent vascular disease did not appear to prevent Alzheimer’s. It concluded that “there is good evidence [from randomised controlled trials] that statins given in late life to individuals at risk of vascular disease have no effect in preventing Alzheimer’s or dementia.” This review sought to identify all high-quality literature published on the topic, and it is unlikely that these conclusions would change on the basis of the new, small animal study.

Similarly, a systematic review also looked at whether statins were effective at treating dementia, using high-quality studies published before March 2009. It included a study that assessed the effect of simvastatin on Alzheimer’s disease. It too concluded that there was insufficient evidence to recommend statins for the treatment of dementia, including Alzheimer’s.

This research is bound to be of great interest to people with Alzheimer’s disease and their loved ones, particularly given the impression they may have gained from reading newspaper accounts of it. Dr Simon Ridley, head of research at Alzheimer’s Research UK, the UK’s leading dementia research charity, has helped put the research into context in a statement issued to Behind the Headlines. He said:

“These kinds of studies, in which some characteristics of Alzheimer’s in mice are prevented or reversed, are often interesting and can help to guide both understanding of the disease as well as future studies in people. While some studies in humans have suggested that statin users may have a lower risk of Alzheimer’s, this has not been consistent.

“However, as with many trials for chronic diseases, there is always the issue of whether there is a critical time to give treatments that offers the best chance of success.

“Although simvastatin is a cholesterol-lowering drug, this study in mice did not explain exactly how simvastatin was having its beneficial effect. Interestingly, there did not seem to be a reduction in cholesterol in the mice treated with simvastatin, suggesting that the drug may be acting through a mechanism independent of its ability to lower cholesterol. Therefore people should view the results with caution until further research has teased out how simvastatin might be working in these mice, and more importantly, until there is any significant new clinical trial data in humans.”

Consequently, while the research may offer scientists some new clues on the development of Alzheimer’s disease, front-page headlines that “Statins halt Alzheimer’s” are not supported by this small animal study or by the weight of existing research on the topic.

Analysis by Bazian

Links To The Headlines

Statins could stave off symptoms of Alzheimer's, study finds. The Daily Telegraph, April 4 2012

Widely-prescribed statins may help to fight Alzheimer's if they're given in early stages. Daily Mail, April 4 2012

Statins halt Alzheimer's. The Daily Express, April 4 2012
 

Links To Science

Tong XK, Lecrux C and Hamel E. Age-Dependent Rescue by Simvastatin of Alzheimer's Disease Cerebrovascular and Memory Deficits. The Journal of Neuroscience, 4 April 2012, 32(14): 4705-4715
=================================================================
Read the complete article here.

Saturday, March 17, 2012

Is the use of cholesterol in mortality risk algorithms in clinical guidelines valid?


J Eval Clin Pract. 2012 Feb;18(1):159-68. doi: 10.1111/j.1365-2753.2011.01767.x. Epub 2011 Sep 25.

Is the use of cholesterol in mortality risk algorithms in clinical guidelines valid? Ten years prospective data from the Norwegian HUNT 2 study.

Source

Research Unit of General Practice, Department of Public Health and General Practice, Norwegian University of Science and Technology (NTNU), Trondheim, Norway. halfdanpe@gmail.com

Abstract

RATIONALE, AIMS AND OBJECTIVES:

Many clinical guidelines for cardiovascular disease (CVD) prevention contain risk estimation charts/calculators. These have shown a tendency to overestimate risk, which indicates that there might be theoretical flaws in the algorithms. Total cholesterol is a frequently used variable in the risk estimates. Some studies indicate that the predictive properties of cholesterol might not be as straightforward as widely assumed. Our aim was to document the strength and validity of total cholesterol as a risk factor for mortality in a well-defined, general Norwegian population without known CVD at baseline.

METHODS:

We assessed the association of total serum cholesterol with total mortality, as well as mortality from CVD and ischaemic heart disease (IHD), using Cox proportional hazard models. The study population comprises 52 087 Norwegians, aged 20-74, who participated in the Nord-Trøndelag Health Study (HUNT 2, 1995-1997) and were followed-up on cause-specific mortality for 10 years (510 297 person-years in total).

RESULTS:

Among women, cholesterol had an inverse association with all-cause mortality [hazard ratio (HR): 0.94; 95% confidence interval (CI): 0.89-0.99 per 1.0 mmol L(-1) increase] as well as CVD mortality (HR: 0.97; 95% CI: 0.88-1.07). The association with IHD mortality (HR: 1.07; 95% CI: 0.92-1.24) was not linear but seemed to follow a 'U-shaped' curve, with the highest mortality <5.0 and ≥7.0 mmol L(-1) . Among men, the association of cholesterol with mortality from CVD (HR: 1.06; 95% CI: 0.98-1.15) and in total (HR: 0.98; 95% CI: 0.93-1.03) followed a 'U-shaped' pattern.

CONCLUSION:

Our study provides an updated epidemiological indication of possible errors in the CVD risk algorithms of many clinical guidelines. If our findings are generalizable, clinical and public health recommendations regarding the 'dangers' of cholesterol should be revised. This is especially true for women, for whom moderately elevated cholesterol (by current standards) may prove to be not only harmless but even beneficial.
© 2011 Blackwell Publishing Ltd.
PMID:
21951982
[PubMed - in process]
PMCID:
PMC3303886
==========================================================
Read the article here.

Thursday, June 23, 2011

Statin drugs are associated with decreased myocardial function

Two recent articles highlight the fact that statin drugs are associated with decreased myocardial function.
Statin use is known to be associated with myopathy, muscle weakness and rhabdomyolysis, a breakdown of muscle fibers resulting in the release of muscle fiber contents into the bloodstream. For the study, myocardial function was evaluated in 28 patients.
According to Green Med Info:
“There was significantly better function noted … in the control group vs the statin group”.
============================================================
From: http://www.greenmedinfo.com/toxic-article/statin-therapy-decreases-myocardial-heart-function
------------------

Statin therapy decreases myocardial (heart) function.

Abstract Title:
Statin therapy decreases myocardial function as evaluated via strain imaging.
Article Link:
Article Source:
Pubmed
Abstract Author(s):
Feras Aloka, George S Abela, Jack Rubinstein
Article Affiliation:
Cardiology Division, Department of Medicine, Michigan State University, East Lansing, MI 48824, USA.
Abstract:
OBJECTIVES: The purpose of this study was to evaluate the effects of statin therapy on myocardial function as measured with echocardiography with tissue Doppler imaging (TDI) and strain imaging (SI) independent of its lipid-lowering effect. BACKGROUND: Statin use is known to improve outcomes in the primary and secondary prevention of ischemic heart disease, but their use is also associated with myopathy, muscle weakness and in rare cases, rhabdomyolysis. We sought to evaluate whether TDI and SI is able to identify changes in myocardial function associated with statin use. METHODS: Myocardial function was evaluated in 28 patients via echocardiography with TDI and SI. We identified 12 patients (5 females) without overt cardiovascular disease (including hypertension, smoking, and diabetes) that were on statin therapy and compared their echocardiographic findings with 16 (12 females) age, sex, and cholesterol-profile-matched controls. Tissue Doppler imaging parameters of diastolic (E(')/A(') and E/E(')) and systolic (S') function were measured. Regional systolic function was obtained by SI in 4-chamber, 2-chamber, long axis, and average global views. RESULTS: There was no significant difference in myocardial function as measured by Doppler and minor differences as measured via TDI among the 2 groups. There was significantly better function noted with SI in the control group vs the statin group in the 4-chamber (-19.05% +/- 2.45% vs -16.47% +/- 2.37% P = 0.009), 2-chamber (-20.30% +/- 2.66% vs -17.45% +/- 4.29% P = 0.03), long axis (-17.63% +/- 3.79% vs -13.83% +/- 3.74% P = 0.01), and average global (-19.0% +/- 2.07% vs -15.91% +/- 2.81% P = 0.004) views. CONCLUSION: Statin therapy is associated with decreased myocardial function as evaluated with SI.
Study Type : Human Study
Toxic Ingredients : Statin Drugs
=======================================================
From: http://www.ncbi.nlm.nih.gov/pubmed/20027659
-----------------------------
Clin Cardiol. 2009 Dec;32(12):684-9.

Statin therapy decreases myocardial function as evaluated via strain imaging.

Source

Cardiology Division, Department of Medicine, Michigan State University, East Lansing, MI 48824, USA.

Abstract

OBJECTIVES:

The purpose of this study was to evaluate the effects of statin therapy on myocardial function as measured with echocardiography with tissue Doppler imaging (TDI) and strain imaging (SI) independent of its lipid-lowering effect.

BACKGROUND:

Statin use is known to improve outcomes in the primary and secondary prevention of ischemic heart disease, but their use is also associated with myopathy, muscle weakness and in rare cases, rhabdomyolysis. We sought to evaluate whether TDI and SI is able to identify changes in myocardial function associated with statin use.

METHODS:

Myocardial function was evaluated in 28 patients via echocardiography with TDI and SI. We identified 12 patients (5 females) without overt cardiovascular disease (including hypertension, smoking, and diabetes) that were on statin therapy and compared their echocardiographic findings with 16 (12 females) age, sex, and cholesterol-profile-matched controls. Tissue Doppler imaging parameters of diastolic (E(')/A(') and E/E(')) and systolic (S') function were measured. Regional systolic function was obtained by SI in 4-chamber, 2-chamber, long axis, and average global views.

RESULTS:

There was no significant difference in myocardial function as measured by Doppler and minor differences as measured via TDI among the 2 groups. There was significantly better function noted with SI in the control group vs the statin group in the 4-chamber (-19.05% +/- 2.45% vs -16.47% +/- 2.37% P = 0.009), 2-chamber (-20.30% +/- 2.66% vs -17.45% +/- 4.29% P = 0.03), long axis (-17.63% +/- 3.79% vs -13.83% +/- 3.74% P = 0.01), and average global (-19.0% +/- 2.07% vs -15.91% +/- 2.81% P = 0.004) views.

CONCLUSION:

Statin therapy is associated with decreased myocardial function as evaluated with SI.

PMID:

 
20027659
 
[PubMed - indexed for MEDLINE]